Drug
Veliparib clinical trials
Also written ABT-888.
- studies test it
- 94
- open now
- 0
- in phase 3
- 6
- first study started
- 2006
How studies write it
Studies that test it under each name
Development codes
- ABT-888
- 153
Combined with it in one product
Studies by the year they started
94 studies that test it; most in 2011 (16)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 5 |
| 2009 | 7 |
| 2010 | 15 |
| 2011 | 16 |
| 2012 | 15 |
| 2013 | 5 |
| 2014 | 10 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 60
- Phase 2
- 40
- Phase 3
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 67
National Cancer Institute (NCI) (45) · AbbVie (16) · AbbVie (prior sponsor, Abbott) (10) · Georgetown University (3) · Vejle Hospital (2) · Children's Oncology Group (1) · University of Alabama at Birmingham (1) · Sidney Kimmel Cancer Center at Thomas Jefferson University (1)
Often tested with
Tested in the same studies.
Temozolomide (17) · Carboplatin (15) · Paclitaxel (8) · Topotecan (6) · Gemcitabine (6) · Cisplatin (5) · Cyclophosphamide (3) · Doxorubicin (3)
Studies
Open first, then newest update. How each study uses veliparib is read from its arms, and is right about nine times in ten.
Testing it · 94
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingPhase 2/3National Cancer Institute (NCI)NCT02152982Written as Veliparib
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01386385Written as Veliparib
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 MutationsActive, not recruitingPhase 2Children's Oncology GroupNCT03581292Written as Veliparib
- Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01638546Written as Veliparib
- Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01012817Written as Veliparib
- Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01585805Written as Veliparib
- Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01351909Written as Veliparib
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01366144Written as Veliparib
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00740805Written as Veliparib
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01434316Written as Veliparib
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT01642251Written as Veliparib
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic LeukemiaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03289910Written as Veliparib
- Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01251874Written as Veliparib
- FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerCompletedPhase 2National Cancer Institute (NCI)NCT02890355Written as Veliparib
- Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain MetastasesCompletedPhase 2National Cancer Institute (NCI)NCT02595905Written as Veliparib
- Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast CancerCompletedNot applicableUniversity of Alabama at BirminghamNCT02158507Written as Combination of Veliparib + Lapatinib
- Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal CancerCompletedPhase 2National Cancer Institute (NCI)NCT02921256Written as Veliparib
- Veliparib and Temozolomide in Treating Patients With Acute LeukemiaCompletedPhase 1National Cancer Institute (NCI)NCT01139970Written as Veliparib
- ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic CancerCompletedPhase 1/2Georgetown UniversityNCT01489865Written as ABT-888
- Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast CancerCompletedPhase 2National Cancer Institute (NCI)NCT01149083Written as Veliparib
See all 94 studies that test veliparib →
Given in every arm · 5 — veliparib is usual care beside what is tested
- Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 1National Cancer Institute (NCI)NCT00989651Written as Veliparib
- Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1AbbVieNCT02944396Written as veliparib
- ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT00770471Written as veliparib
- A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid TumorsCompletedPhase 1AbbVieNCT02033551Written as Veliparib
- Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01017640Written as Veliparib
As the comparator · 1 — what is tested is compared with veliparib
Codes
What other systems call veliparib · ClinicalTrials.gg INT005114
- MeSH (NLM) C521013veliparibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 01O4K0631NVELIPARIBConfirmed FDA, NLM, Wikidata
- Wikidata Q7919041veliparibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C60768VeliparibOne source FDA
- DrugBank DB07232One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C521013 | veliparib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 01O4K0631N | VELIPARIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7919041 | veliparib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C60768 | Veliparib | One source FDA |
| DrugBank | DB07232 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.